Which has better valuation and earnings, ARGX or INSM?

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.57 $1.29B $26.04 32.79 Insmed $606.42M 35.24 -$1.28B -$5.75 N/A

Is ARGX or INSM more profitable?

argenex has a net margin of 32.19% compared to Insmed's net margin of -144.44%. argenex's return on equity of 43.59% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Insmed -144.44% -130.11% -51.57%

Does the media refer more to ARGX or INSM?

In the previous week, argenex had 28 more articles in the media than Insmed. MarketBeat recorded 41 mentions for argenex and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat argenex's score of 0.89 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 20 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TAK or INSM?

Insmed has a consensus target price of $209.35, suggesting a potential upside of 112.32%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Insmed 1 Sell rating(s) 0 Hold rating(s) 23 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media refer more to TAK or INSM?

In the previous week, Takeda Pharmaceutical had 5 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Takeda Pharmaceutical and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat Takeda Pharmaceutical's score of 0.63 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or INSM?

In the previous week, Revolution Medicines had 8 more articles in the media than Insmed. MarketBeat recorded 21 mentions for Revolution Medicines and 13 mentions for Insmed. Revolution Medicines' average media sentiment score of 1.33 beat Insmed's score of 1.28 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, INSM or ONC?

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 35.24 -$1.28B -$5.75 N/A BeOne Medicines $5.34B 6.49 $286.93M $4.47 70.70

Is INSM or ONC more profitable?

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% BeOne Medicines 8.94% 12.06% 6.69%

Does the media prefer INSM or ONC?

In the previous week, BeOne Medicines had 2 more articles in the media than Insmed. MarketBeat recorded 15 mentions for BeOne Medicines and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat BeOne Medicines' score of 0.90 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INSM or TEVA?

In the previous week, Teva Pharmaceutical Industries had 35 more articles in the media than Insmed. MarketBeat recorded 48 mentions for Teva Pharmaceutical Industries and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat Teva Pharmaceutical Industries' score of 0.77 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 26 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Insmed (INSM) Competitors

$98.60 -2.89 (-2.85%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$98.03 -0.57 (-0.58%)

As of 07/31/2026 07:34 PM Eastern

Compare

INSM vs. ARGX, TAK, RVMD, ONC, and TEVA

Should you buy Insmed stock or one of its competitors? MarketBeat compares Insmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insmed include argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), BeOne Medicines (ONC), and Teva Pharmaceutical Industries (TEVA).

How does Insmed compare to argenex?

argenex (NASDAQ:ARGX) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, argenex had 28 more articles in the media than Insmed. MarketBeat recorded 41 mentions for argenex and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat argenex's score of 0.89 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	20 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.57	$1.29B	$26.04	32.79
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A

argenex presently has a consensus target price of $1,056.89, suggesting a potential upside of 23.78%. Insmed has a consensus target price of $209.35, suggesting a potential upside of 112.32%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

60.3% of argenex shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Insmed's net margin of -144.44%. argenex's return on equity of 43.59% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Insmed	-144.44%	-130.11%	-51.57%

Summary

argenex beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Insmed has a consensus target price of $209.35, suggesting a potential upside of 112.32%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Takeda Pharmaceutical has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

In the previous week, Takeda Pharmaceutical had 5 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Takeda Pharmaceutical and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat Takeda Pharmaceutical's score of 0.63 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.93	-$1.01B	$0.39	43.83
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A

9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 3.80% compared to Insmed's net margin of -144.44%. Takeda Pharmaceutical's return on equity of 10.87% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.87%	5.32%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Takeda Pharmaceutical beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Revolution Medicines had 8 more articles in the media than Insmed. MarketBeat recorded 21 mentions for Revolution Medicines and 13 mentions for Insmed. Revolution Medicines' average media sentiment score of 1.33 beat Insmed's score of 1.28 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	17 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Revolution Medicines presently has a consensus price target of $144.67, suggesting a potential downside of 22.85%. Insmed has a consensus price target of $209.35, suggesting a potential upside of 112.32%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Revolution Medicines' return on equity of -83.22% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Insmed	-144.44%	-130.11%	-51.57%

Revolution Medicines has higher earnings, but lower revenue than Insmed. Revolution Medicines is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,442.91	-$1.13B	-$7.07	N/A
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A

Summary

Revolution Medicines beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Insmed compare to BeOne Medicines?

Insmed (NASDAQ:INSM) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
BeOne Medicines	8.94%	12.06%	6.69%

Insmed currently has a consensus target price of $209.35, suggesting a potential upside of 112.32%. BeOne Medicines has a consensus target price of $394.00, suggesting a potential upside of 24.68%. Given Insmed's stronger consensus rating and higher probable upside, research analysts clearly believe Insmed is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88

Insmed has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A
BeOne Medicines	$5.34B	6.49	$286.93M	$4.47	70.70

In the previous week, BeOne Medicines had 2 more articles in the media than Insmed. MarketBeat recorded 15 mentions for BeOne Medicines and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat BeOne Medicines' score of 0.90 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.6% of BeOne Medicines shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BeOne Medicines beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to Teva Pharmaceutical Industries?

Insmed (NASDAQ:INSM) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Teva Pharmaceutical Industries has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A
Teva Pharmaceutical Industries	$17.26B	2.33	$1.41B	$0.60	58.41

In the previous week, Teva Pharmaceutical Industries had 35 more articles in the media than Insmed. MarketBeat recorded 48 mentions for Teva Pharmaceutical Industries and 13 mentions for Insmed. Insmed's average media sentiment score of 1.28 beat Teva Pharmaceutical Industries' score of 0.77 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	26 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Insmed currently has a consensus target price of $209.35, indicating a potential upside of 112.32%. Teva Pharmaceutical Industries has a consensus target price of $42.00, indicating a potential upside of 19.84%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Insmed's net margin of -144.44%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Summary

Teva Pharmaceutical Industries beats Insmed on 10 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.37B	$3.55B	$7.17B	$12.47B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-17.15	7.38	282.25	24.53
Price / Sales	35.24	1,266.83	587.75	90.70
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	28.50	16.78	10.93	6.07
Net Income	-$1.28B	-$12.56M	$3.50B	$348.34M
7 Day Performance	-7.78%	-1.47%	-0.24%	0.09%
1 Month Performance	-11.65%	-8.45%	-3.70%	-5.17%
1 Year Performance	-9.28%	48.32%	61.98%	18.61%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	3.8255 of 5 stars	$98.60 -2.8%	$209.35 +112.3%	-9.3%	$21.37B	$606.42M	N/A	1,664	News Coverage Positive News Upcoming Earnings Analyst Forecast
ARGX argenex	4.5423 of 5 stars	$888.82 -3.2%	$1,054.11 +18.6%	+26.7%	$57.44B	$4.25B	34.13	1,863	Analyst Forecast Analyst Revision
TAK Takeda Pharmaceutical	1.8913 of 5 stars	$17.45 +1.2%	N/A	+20.6%	$55.24B	$28.32B	44.75	47,000	Trending News Analyst Downgrade
RVMD Revolution Medicines	1.7878 of 5 stars	$188.07 -0.6%	$144.67 -23.1%	+412.0%	$40.23B	$11.58M	N/A	250	News Coverage Positive News Upcoming Earnings
ONC BeOne Medicines	4.6383 of 5 stars	$325.90 flat	$394.00 +20.9%	+5.7%	$35.76B	$5.34B	72.91	12,000	Upcoming Earnings Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors

INSM vs. ARGX, TAK, RVMD, ONC, and TEVA

How does Insmed compare to argenex?

Summary

How does Insmed compare to Takeda Pharmaceutical?

Summary

How does Insmed compare to Revolution Medicines?

Summary

How does Insmed compare to BeOne Medicines?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Competitors

INSM vs. ARGX, TAK, RVMD, ONC, and TEVA

How does Insmed compare to argenex?

Does the media refer more to ARGX or INSM?

Which has better valuation and earnings, ARGX or INSM?

Do analysts rate ARGX or INSM?

Which has more risk and volatility, ARGX or INSM?

Do institutionals and insiders have more ownership in ARGX or INSM?

Is ARGX or INSM more profitable?

Summary

How does Insmed compare to Takeda Pharmaceutical?

Do analysts recommend TAK or INSM?

Which has more volatility & risk, TAK or INSM?

Does the media refer more to TAK or INSM?

Which has preferable valuation & earnings, TAK or INSM?

Do insiders & institutionals have more ownership in TAK or INSM?

Is TAK or INSM more profitable?

Summary

How does Insmed compare to Revolution Medicines?

Does the media favor RVMD or INSM?

Which has more volatility & risk, RVMD or INSM?

Do insiders and institutionals have more ownership in RVMD or INSM?

Do analysts prefer RVMD or INSM?

Is RVMD or INSM more profitable?

Which has stronger earnings & valuation, RVMD or INSM?

Summary

How does Insmed compare to BeOne Medicines?

Is INSM or ONC more profitable?

Do analysts prefer INSM or ONC?

Which has more risk and volatility, INSM or ONC?

Which has stronger earnings and valuation, INSM or ONC?

Does the media prefer INSM or ONC?

Do insiders and institutionals hold more shares of INSM or ONC?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Which has better valuation and earnings, INSM or TEVA?

Does the media prefer INSM or TEVA?

Do insiders & institutionals believe in INSM or TEVA?

Do analysts rate INSM or TEVA?

Which has more risk and volatility, INSM or TEVA?

Is INSM or TEVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools